story of the week
Neratinib Alone and in Combination With Fulvestrant in HER2-Mutated, Non-Amplified Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer
Clin. Cancer Res 2022 Jan 19;[EPub Ahead of Print], CX Ma, J Luo, RA Freedman, TJ Pluard, JR Nangia, J Lu, F Valdez-Albini, M Cobleigh, JM Jones, NU Lin, EP Winer, PK Marcom, J Anderson, S Thomas, B Haas, L Bucheit, R Bryce, AS Lalani, LA Carey, MP Goetz, F Gao, G Kimmick, MD Pegram, MJ Ellis, R BoseFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.